Notice of Approval for Clinical Trials of Class 1 Innovative Drugs by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd

Recently, Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. received a Drug Clinical Trial Approval Notice from the National Medical Products Administration, agreeing to conduct clinical trials on QJ-19-0002 tablets for gout patients with hyperuricemia.

QJ-19-0002 tablets are a Class 1 innovative drug developed by Zhongda Qingjiang Pharmaceutical. They are an efficient and highly selective inhibitor of urate transporter 1 (URAT1), a new generation of urate excretion enhancers. By targeting the inhibition of URAT1, they normalize the excretion of urate in urine, thereby reducing serum uric acid levels. It is expected to become a Class 1 innovative drug with independent intellectual property rights in China, which is safe, effective, and reasonably priced for the treatment of hyperuricemia and gout.

Since its establishment, the company has always focused on advantageous areas and actively sought expansion, gradually shifting from "imitation oriented" to "combination of imitation and innovation.". Focusing on the two core areas of orthopedics and pediatrics, actively exploring the fields of medication such as fine anesthesia and ophthalmology, while expanding product formulations. This product is the company's first declared Class 1 new chemical drug, which also marks a new step in the company's research and development innovation transformation.